Compare · DXCM vs SGP
DXCM vs SGP
Side-by-side comparison of DexCom Inc. (DXCM) and SpyGlass Pharma Inc. (SGP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SGP operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $23.76B, about 30.2x SGP ($786.2M).
- Over the past year, DXCM is down 13.5% and SGP is down 10.3% - SGP leads by 3.2 points.
- DXCM has hit the wire 4 times in the past 4 weeks while SGP has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 5 for SGP).
- Company
- DexCom Inc.
- SpyGlass Pharma Inc.
- Price
- $61.55-1.84%
- $23.43-3.42%
- Market cap
- $23.76B
- $786.2M
- 1M return
- -7.89%
- -6.60%
- 1Y return
- -13.51%
- -10.26%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2026
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 5
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)
Latest SGP
- SEC Form 10-K filed by SpyGlass Pharma Inc.
- SpyGlass Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
- H.C. Wainwright initiated coverage on SpyGlass Pharma with a new price target
- SpyGlass Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
- SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit
- Stifel initiated coverage on SpyGlass Pharma with a new price target
- Citigroup initiated coverage on SpyGlass Pharma with a new price target
- Jefferies initiated coverage on SpyGlass Pharma with a new price target